Anti-AKT3 + AKT2 + AKT1 antibody [Y89] - BSA and Azide free
- RabMAb
- Recombinant
- What is this?
Be the first to review this product! Submit a review
|
(27 Publications)
Rabbit Recombinant Monoclonal AKT1 antibody. Carrier free. Suitable for IHC-P, IP, WB, ICC/IF, Flow Cyt (Intra) and reacts with Human samples. Cited in 27 publications.
View Alternative Names
PKB, RAC, AKT1, RAC-alpha serine/threonine-protein kinase, Protein kinase B, Protein kinase B alpha, Proto-oncogene c-Akt, RAC-PK-alpha, PKB alpha
- ICC/IF
Unknown
Immunocytochemistry/ Immunofluorescence - Anti-AKT3 + AKT2 + AKT1 antibody [Y89] - BSA and Azide free (AB219588)
ab32505 staining in SK-N-SH cells treated with alsterpaullone (ab141070), by ICC/IF. Decrease of AKT1 + AKT2 + AKT3 expression correlates with increased concentration of alsterpaullone, as described in literature.
The cells were incubated at 37°C for 6h in media containing different concentrations of ab141070 (alsterpaullone) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab32505 (1/200 dilution was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab32505).
- Flow Cyt (Intra)
Unknown
Flow Cytometry (Intracellular) - Anti-AKT3 + AKT2 + AKT1 antibody [Y89] - BSA and Azide free (AB219588)
Overlay histogram showing HeLa cells stained with ab32505 (red line). The cells were fixed with methanol (5 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab32505, 1/20 dilution) for 30 min at 22°C. The secondary antibody used was DyLight® 488 goat anti-rabbit IgG (H+L) (ab96899) at 1/500 dilution for 30 min at 22°C. Isotype control antibody (black line) was rabbit monoclonal IgG (1μg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed. This antibody gave a slightly decreased signal in HeLa cells fixed with 4% paraformaldehyde (10 min)/permeabilized in 0.1% PBS-Tween used under the same conditions. This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab32505).
- IHC-P
Unknown
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-AKT3 + AKT2 + AKT1 antibody [Y89] - BSA and Azide free (AB219588)
Immunohistochemical analysis of paraffin-embedded prostate carcinoma using ab32505 at 1/100 dilution.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab32505).
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
- IP
Unknown
Immunoprecipitation - Anti-AKT3 + AKT2 + AKT1 antibody [Y89] - BSA and Azide free (AB219588)
Purified ab32505 at 1/50 dilution (2μg) immunoprecipitating AKT3+AKT2+AKT1 in MCF7 whole cell lysate.
Lane 1 (input) : MCF7 (Human breast adenocarcinoma epithelial cell) whole cell lysate 10μg
Lane 2 (+) : ab32505 + MCF7 whole cell lysate.
Lane 3 (-) : Rabbit monoclonal IgG (ab172730) instead of ab32505 in MCF7 whole cell lysate.
VeriBlot for IP Detection Reagent (HRP) (ab131366) (1/1000 dilution) was used for Western blotting.
Blocking Buffer and concentration : 5% NFDM/TBST.
Diluting buffer and concentration : 5% NFDM/TBST.
Observed band size : 59 kDa
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab32505).
All lanes:
Immunoprecipitation - Anti-AKT3 + AKT2 + AKT1 antibody [Y89] (<a href='/en-us/products/primary-antibodies/akt3-akt2-akt1-antibody-y89-ab32505'>ab32505</a>)
false
- WB
CiteAb
Western blot - Anti-AKT3 + AKT2 + AKT1 antibody [Y89] - BSA and Azide free (AB219588)
AKT3 + AKT2 + AKT1 western blot using anti-AKT3 + AKT2 + AKT1 antibody [Y89] - BSA and Azide free ab219588. Publication image and figure legend from Khanom, R., Nguyen, C. T., et al., 2016, PLoS One, PubMed 27512993.
ab219588 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab219588 please see the product overview.
KRT17 knockout inhibited tumor growth.(A) Confirmation of KRT17 mutation in the KRT17-knockout cells (HSC3-KO). HSC3 was transfected with pSpCas9(BB)-2A-GFP carrying the KRT17 target sequence in KRT17 exon 3 and cloned by limited dilution following fluorescence activated cell sorting of transfected cells. Six independent clones, in which KRT17 protein expression was absent, were established. Of those, one clone (HSC3-KO) exhibited homo-allelic single-base deletion as revealed by PCR and direct sequencing of the genomic DNA, resulting in a frame shift and a premature stop codon. +259 and +278 denote the nucleotide positions corresponding to KRT17 cDNA when the A of the ATG of the initiator methionine codon is designated as position +1. (B) Western blot analysis of HSC3 and HSC3-KO, demonstrating the absence of KRT17 and reduced expression of phosphorylated pAKT1, MTOR, and pEIF4EBP1 in HSC3-KO. (C) Reduced SLC2A1 expression and glucose uptake in HSC3-KO, as revealed by flow cytometry. (D) Cells (5 x 105) of HSC3 or HSC-KO were subcutaneously injected into the cephalic skin of nude mice (n = 4). One mouse transplanted with HSC3 died of an unknown cause on day 10. HSC3-KO cells developed smaller tumors than HSC3. The photographs were taken on day 15. The tumor areas are encircled by yellow dashed lines. (E) The tumor area was calculated following elliptic substitution of the macroscopic tumor margin using the photograph of the vertical view. The bold lines depict mean tumor areas. The error bars represent standard errors. (F) Immunohistochemical examination of the HSC3-KO tumor developed in the nude mice, confirming negative expression of KRT17. Since the antibody recognizes both human and mouse KRT17, the physiological expression of KRT17 was observed in the hair follicles. Scale bar, 200 μm. (G) Histology of the HSC3 tumor and the HSC3-KO tumor. The HSC3 tumor was composed of medium-to-large-sized tumor nests, whereas the HSC3-KO tumor was composed of small islands. Scale bar, 200 μm. (H) Immunohistochemical expression of MKI67 in the HSC3 tumor and the HSC3-KO tumor. Note that there were fewer cancer cells in the HSC3-KO photograph than in the HSC3 photograph. Scale bar, 200 μm. (I) The Ki-67 labeling indices (LI) were calculated as the percentage of MKI67-positive nuclei in the cancer cells after counting at least 1,000 tumor cells at X200 magnification. The tumor areas that were closest to the epidermis were used for analysis.
false
Related conjugates and formulations (3)
-
Anti-AKT3 + AKT2 + AKT1 antibody [Y89]
-
578 PE
PE Anti-AKT3 + AKT2 + AKT1 antibody [Y89]
-
519 Alexa Fluor® 488
Alexa Fluor® 488 Anti-AKT3 + AKT2 + AKT1 antibody [Y89]
Reactivity data
Product details
ab219588 is the carrier-free version of ab32505.
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
The AKT kinase family plays a major role in regulating vital cellular functions including metabolism cell proliferation survival and growth. It does so by catalyzing phosphorylation of a range of substrates within these pathways. AKT is often involved in complexes with other proteins to achieve these biological effects. It impacts the regulation of glycogen synthase kinase 3 (GSK3) involved in insulin response and mTOR which controls cell growth. These wide-ranging functions make AKT proteins essential in maintaining cellular homeostasis.
Pathways
AKT proteins are important components of the PI3K/AKT/mTOR signaling pathway and the insulin signaling pathway. Within these pathways they interact with and modulate activities of related proteins such as PI3K PDK1 and mTOR. This regulation helps control the balance between anabolic and catabolic processes influencing cell survival growth and metabolism. The importance of AKT kinases in these pathways marks them as key regulators of cellular responses to external and internal stimuli.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Additional targets
Publications (27)
Recent publications for all applications. Explore the full list and refine your search
Biotechnology and applied biochemistry 67:1000-1010 PubMed31845407
2020
Applications
Unspecified application
Species
Unspecified reactive species
PloS one 11:e0161163 PubMed27512993
2016
Applications
Unspecified application
Species
Unspecified reactive species
PloS one 11:e0159568 PubMed27454120
2016
Applications
WB
Species
Mouse
European journal of medicinal chemistry 122:684-701 PubMed27448924
2016
Applications
WB
Species
Human
Oncology letters 12:1139-1143 PubMed27446408
2016
Applications
WB
Species
Human
Scientific reports 6:23817 PubMed27026509
2016
Applications
WB
Species
Rat
Experimental and therapeutic medicine 11:2503-2508 PubMed27284339
2016
Applications
WB
Species
Human
Biochemical and biophysical research communication 474:1-7 PubMed26993162
2016
Applications
WB
Species
Human
Biology of sex differences 7:16 PubMed26949510
2016
Applications
Unspecified application
Species
Mouse
Scientific reports 6:21914 PubMed26902855
2016
Applications
WB
Species
Mouse
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com